+58%

est. 2Y upside i

HealthcareSeries A

We deliver personalized medicine for neurodegenerative patients

Rank

#871

Sector

Neurodegenerative Disease Telehealth

Est. Liquidity

~6Y

Data Quality

Data: Low

Synapticure is an early-stage Series A company with $25M in revenue and strong clinical partnerships, but the absence of a disclosed valuation, unknown growth rate, and estimated 37% preference stack ratio (severe) against an implied ~$125M post-money mean common equity only meaningfully participates above a ~$125M exit threshold.

Last updated: May 14, 2026

Bull (17%)+350%

A strategic acquirer — pharma (e.g., Lilly, Biogen) or a large health system — acquires Synapticure at ~$450M (~18x $25M revenue) within 2 years, driven by surging M&A demand for neurodegenerative assets and Synapticure's 50-state reach. After clearing $46.3M in liquidation preferences, common stockholders net roughly $400M, or approximately 5x their 409A-implied equity value.

Base (53%)+40%

Synapticure raises a Series B at approximately $200–225M by late 2026, growing revenue toward $40M as the Medicare GUIDE program scales nationally and health plan contracts expand. Common stock sees ~40% paper appreciation, but true liquidity remains 4–6 years away, suppressing any realized return meaningfully below this figure.

Bear (30%)-75%

Reimbursement headwinds from CMS, slower commercial ramp, or inability to raise a Series B on acceptable terms forces a flat or down round — the $46.3M preference stack severely erodes common equity value. In a distressed sale or bridge scenario below ~$75M enterprise value, common shareholders are effectively wiped out.

Est. time to liquidity~6.0 years

Preference Stack Risk

severe

Funding Intensity

37%

$46.3M in total liquidation preferences against an estimated ~$125M post-money valuation means preferred holders absorb the first ~37 cents of every exit dollar before common shareholders receive anything.

Dilution Risk

high

A Series A company with $46.3M raised will almost certainly require 2–3 additional funding rounds before a liquidity event, likely diluting current common stockholders by 35–55% cumulatively.

Secondary Liquidity

none

No evidence of secondary market activity, tender offers, or structured liquidity programs for a 93-person private Series A company with no disclosed secondary platform.

CARE Delivery — 10 roles

Operations — 3 roles

Finance — 1 role

Product and Technology — 1 role

View all 17 open roles at Synapticure →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Synapticure's data — designed to show you've done your homework.

  • 1

    “What is the current revenue run rate and YoY growth, and what does management's path to profitability look like relative to the $25M Series A raise?”

  • 2

    “How is revenue recognized under health plan and ACO contracts — is it per-member-per-month, per-episode, or fee-for-service, and what is the CMS reimbursement certainty for the GUIDE program?”

  • 3

    “What is the confirmed post-money valuation from the November 2024 Series A, and what is the current 409A strike price for option grants issued to new hires?”

Community

Valuation Sentiment

Our model estimates +58% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.